8-K: Silence Therapeutics Announces Positive Phase 2 Trial Results for Divesiran

Silence Therapeutics plc reported positive topline results from the Phase 2 SANRECO trial of divesiran for polycythemia vera, meeting primary and secondary endpoints and supporting advancement to Phase 3.

Summary

• Silence Therapeutics plc announced positive topline results from the Phase 2 SANRECO trial for its drug divesiran in treating polycythemia vera (PV).
• The trial met its primary endpoint, showing a significantly higher proportion of clinical responders (88%) in the divesiran groups compared to placebo (19%).
• Both Q6W and Q12W dosing regimens of divesiran demonstrated substantial efficacy, with response rates of 93.8% and 81.3%, respectively.
• A key secondary endpoint was also met, with a significant reduction in phlebotomy rates for divesiran-treated patients (0.2 per patient) compared to placebo (2.1 per patient).
• Improvements were also observed in hematocrit control, iron markers, and patient-reported outcomes.
• Divesiran was well-tolerated, with a safety profile consistent with previous trials and no new safety findings.
• Based on these results, Silence Therapeutics plans to initiate a Phase 3 trial for divesiran in the first half of 2027.
• The company will present full results at an upcoming medical congress and hosted a conference call on August 10, 2026.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive development, with strong clinical trial results indicating significant potential for the drug.

Positives

• The Phase 2 SANRECO trial met its primary endpoint with a statistically significant difference in clinical responders between divesiran (88%) and placebo (19%) groups (p<0.0001).
• Both Q6W (93.8%) and Q12W (81.3%) dosing regimens of divesiran showed strong efficacy.
• The key secondary endpoint of reduced phlebotomy rates was met, with divesiran patients requiring significantly fewer phlebotomies (0.2 vs. 2.1 per patient).
• Divesiran demonstrated improvements in hematocrit control, iron markers (ferritin), and patient-reported outcomes (MPN-SAF TSS).
• The drug was well-tolerated with no new safety concerns identified; injection site reactions were infrequent and self-limiting.
• The company is planning to initiate a Phase 3 trial in the first half of 2027, indicating confidence in the drug's potential.
• Divesiran has received FDA Fast Track and Orphan Drug designations for PV.

Negatives

• Two investigator-reported grade 1 anemia adverse event cases were noted, though considered minor.
• While generally well-tolerated, the long-term safety profile will continue to be monitored in the Phase 3 trial.

Risks

• The company's ability to obtain necessary capital to fund its clinical programs.
• Potential for undesirable side effects or other properties of the product candidates that may emerge in later-stage trials.
• Reliance on third-party suppliers and manufacturers for drug production.
• The outcomes of future collaboration agreements and the performance of existing partners.
• The company's ability to adequately maintain intellectual property rights for its product candidates.
• Challenges in obtaining and maintaining required regulatory approvals for divesiran.
• Product and pricing initiatives by competitors in the PV market.

Future Outlook

The company expects to initiate a Phase 3 trial evaluating divesiran for Q12W dosing versus placebo in the first half of 2027. Full results from the Phase 2 SANRECO trial will be presented at an upcoming medical congress.

Management Comments

• "These compelling results highlight divesiran's potential to transform PV management with convenient, infrequent dosing that reliably controls hematocrit and addresses longstanding unmet needs for patients."
• "These results reinforce divesiran's potential to become the first and best-in-class siRNA treatment for PV. We look forward to initiating Phase 3 development and bringing divesiran to patients as quickly as possible."

Industry Context

StockSavvy.ai notes that the positive results for divesiran in polycythemia vera align with the growing trend of targeted therapies in hematology. The success of siRNA technology in achieving durable gene silencing with infrequent dosing could position Silence Therapeutics as a leader in this niche, especially given the unmet needs in PV management and the market potential indicated by existing treatments like Jakafi.

Comparison to Industry Standards

• The response rate of 88% for divesiran in the Phase 2 SANRECO trial significantly outperforms the placebo response rate of 19%, demonstrating a substantial clinical benefit.
• The reduction in phlebotomy rates (0.2 vs. 2.1 per patient) indicates a marked improvement in disease management compared to standard care, which often relies heavily on phlebotomies.
• The potential for Q12W (quarterly) dosing offers a significant convenience advantage over more frequent treatments, aligning with industry efforts to improve patient compliance and quality of life.
• While specific competitor data for this exact endpoint in PV is not detailed, the efficacy and safety profile presented positions divesiran as a potential best-in-class therapy, aiming to capture a significant share of the PV market, which is currently served by treatments like Jakafi (ruxolitinib) that generate substantial revenue.

Stakeholder Impact

• Shareholders: Positive trial results are likely to be viewed favorably, potentially increasing investor confidence and share value.
• Patients: The positive results offer hope for a more effective and convenient treatment option for polycythemia vera, potentially improving quality of life.
• Healthcare Providers: The data supports divesiran as a promising new therapeutic option for managing PV, offering an alternative to current standards of care.
• Competitors: The strong efficacy and potential best-in-class profile of divesiran may necessitate strategic adjustments from companies with competing treatments in the PV market.

Next Steps

• Present full results from the Phase 2 SANRECO trial at an upcoming medical congress.
• Complete End of Phase 2 meeting by year-end.
• Initiate a Phase 3 trial evaluating divesiran for Q12W dosing vs. placebo in the first half of 2027.

Key Dates

Recommendation

The filing details highly positive Phase 2 results for divesiran in polycythemia vera, meeting all key efficacy and safety endpoints with a favorable tolerability profile. The drug demonstrated significant improvements in hematocrit control and reduced phlebotomy needs, with potential for convenient Q12W dosing. The planned progression to Phase 3, coupled with FDA Fast Track and Orphan Drug designations, strongly suggests a high probability of success and market potential, warranting a strong buy recommendation.

Keywords

Polycythemia Vera, Divesiran, siRNA, Hematocrit, Phlebotomy, Clinical Trial, Biotechnology, Hematology